Cargando…
High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis
Hepatocellular carcinoma (HCC) is a common malignant tumor in the clinic. Although there are increasing numbers of available treatment methods, their therapeutic effects are not satisfactory. The clinical indicators commonly used to predict the prognosis of HCC include tumor size, degree of cirrhosi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500035/ https://www.ncbi.nlm.nih.gov/pubmed/32968454 http://dx.doi.org/10.3892/ol.2020.12095 |
_version_ | 1783583785872261120 |
---|---|
author | Cai, Hongyu Shao, Bingfeng Zhou, Yuan Chen, Zhong |
author_facet | Cai, Hongyu Shao, Bingfeng Zhou, Yuan Chen, Zhong |
author_sort | Cai, Hongyu |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is a common malignant tumor in the clinic. Although there are increasing numbers of available treatment methods, their therapeutic effects are not satisfactory. The clinical indicators commonly used to predict the prognosis of HCC include tumor size, degree of cirrhosis, degree of tumor differentiation and tumor microvascular invasion; however, there are currently no molecular indicators that can predict the prognosis of HCC. Due to the differences in the progression of liver cancer among individuals, there is a growing need for prognostic biomarkers to accurately stratify patients for appropriate risk-adaptive treatment. The DNA topoisomerase 2-α (TOP2A) gene, which is located on human chromosome 17, encodes DNA topoisomerase IIα. Previous studies have demonstrated that TOP2A indicates a poor prognosis in patients with various types of tumors, but no such studies are currently available on HCC. By analyzing the differential expression of TOP2A in 50 pairs of tumor and paracancerous tissue samples in The Cancer Genome Atlas (TCGA) database, the present study revealed that the expression of TOP2A was significantly higher in tumor tissue compared with that in paracancerous tissue (P=6.319×10(−16)). In the collected clinical samples, the mRNA expression levels of TOP2A were significantly upregulated in HCC tumor tissues compared with those in the paracancerous tissues (P=6.40×10(−3)), suggesting that TOP2A was associated with the occurrence and development of liver cancer. In addition, the associations between TOP2A expression, clinicopathological features and prognosis were analyzed using a multi-center large sample dataset from TCGA database, and the results demonstrated that high expression of TOP2A was associated with a higher T stage, poorer clinical stage and higher histological grade compared with those in patients with low TOP2A expression. High expression of TOP2A was also identified to be associated with a poor prognosis of HCC, particularly in Asian populations. These results suggested that high expression of TOP2A in HCC tissues may be closely associated with tumor progression and metastasis, which may be used as a biological indicator to predict tumor prognosis in clinical practice. |
format | Online Article Text |
id | pubmed-7500035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-75000352020-09-22 High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis Cai, Hongyu Shao, Bingfeng Zhou, Yuan Chen, Zhong Oncol Lett Articles Hepatocellular carcinoma (HCC) is a common malignant tumor in the clinic. Although there are increasing numbers of available treatment methods, their therapeutic effects are not satisfactory. The clinical indicators commonly used to predict the prognosis of HCC include tumor size, degree of cirrhosis, degree of tumor differentiation and tumor microvascular invasion; however, there are currently no molecular indicators that can predict the prognosis of HCC. Due to the differences in the progression of liver cancer among individuals, there is a growing need for prognostic biomarkers to accurately stratify patients for appropriate risk-adaptive treatment. The DNA topoisomerase 2-α (TOP2A) gene, which is located on human chromosome 17, encodes DNA topoisomerase IIα. Previous studies have demonstrated that TOP2A indicates a poor prognosis in patients with various types of tumors, but no such studies are currently available on HCC. By analyzing the differential expression of TOP2A in 50 pairs of tumor and paracancerous tissue samples in The Cancer Genome Atlas (TCGA) database, the present study revealed that the expression of TOP2A was significantly higher in tumor tissue compared with that in paracancerous tissue (P=6.319×10(−16)). In the collected clinical samples, the mRNA expression levels of TOP2A were significantly upregulated in HCC tumor tissues compared with those in the paracancerous tissues (P=6.40×10(−3)), suggesting that TOP2A was associated with the occurrence and development of liver cancer. In addition, the associations between TOP2A expression, clinicopathological features and prognosis were analyzed using a multi-center large sample dataset from TCGA database, and the results demonstrated that high expression of TOP2A was associated with a higher T stage, poorer clinical stage and higher histological grade compared with those in patients with low TOP2A expression. High expression of TOP2A was also identified to be associated with a poor prognosis of HCC, particularly in Asian populations. These results suggested that high expression of TOP2A in HCC tissues may be closely associated with tumor progression and metastasis, which may be used as a biological indicator to predict tumor prognosis in clinical practice. D.A. Spandidos 2020-11 2020-09-11 /pmc/articles/PMC7500035/ /pubmed/32968454 http://dx.doi.org/10.3892/ol.2020.12095 Text en Copyright: © Cai et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Cai, Hongyu Shao, Bingfeng Zhou, Yuan Chen, Zhong High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis |
title | High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis |
title_full | High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis |
title_fullStr | High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis |
title_full_unstemmed | High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis |
title_short | High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis |
title_sort | high expression of top2a in hepatocellular carcinoma is associated with disease progression and poor prognosis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500035/ https://www.ncbi.nlm.nih.gov/pubmed/32968454 http://dx.doi.org/10.3892/ol.2020.12095 |
work_keys_str_mv | AT caihongyu highexpressionoftop2ainhepatocellularcarcinomaisassociatedwithdiseaseprogressionandpoorprognosis AT shaobingfeng highexpressionoftop2ainhepatocellularcarcinomaisassociatedwithdiseaseprogressionandpoorprognosis AT zhouyuan highexpressionoftop2ainhepatocellularcarcinomaisassociatedwithdiseaseprogressionandpoorprognosis AT chenzhong highexpressionoftop2ainhepatocellularcarcinomaisassociatedwithdiseaseprogressionandpoorprognosis |